mycosis fungoides market 2027
DelveInsight's 'Mycosis Fungoides (MF) - Market Insights, Epidemiology and Market Forecast-2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Mycosis Fungoides (MF) in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Mycosis Fungoides (MF) from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Geography Covered
• The United States
• EU5 (Germany, France, Italy, Spain and the United Kingdom)
• Japan
Study Period: 2017-2028
Mycosis Fungoides (MF) - Disease Understanding and Treatment Algorithm
According to the WHO-EORTC classification for cutaneous lymphomas, Mycosis fungoides (MF) is a commonly epidermotropic CTCL characterized by a proliferation of small-to medium-sized T lymphocytes with cerebriform nuclei. As per the guidelines the term MF should be used only for the classical “Alibert-Bazin” type characterized by the evolution of patches, plaques, and tumors, or for variants showing a similar clinical course. MF is the most common type of CTCL and accounts for almost 50% of all primary cutaneous lymphomas.
MF generally shows a male predominance (male: female ratio 2:1) and primarily develops after the fourth decade in life. It was first described by Alibert in 1806 as the infiltration of skin by lymphocytes and named so due to its mushroom-like appearance. Initial lesions are nonspecific eczematous patches followed by the more specific plaque and tumor stage, except for 10% of patients that directly manifest with tumor. A papillary dermal infiltrate with small-to medium-sized lymphocytes with hyperchromatic and hyperconvoluted nuclei is the characteristic histological feature. Epidermotropism seen in the plaque stage is usually lost in the tumor stage.
The DelveInsight Mycosis Fungoides (MF) market report gives a thorough understanding of the Mycosis Fungoides (MF) by including details such as disease definition, types, staging, causes, clinical features, pathogenesis, symptoms and diagnostic trends. It also provides treatment algorithms and treatment guidelines for Mycosis Fungoides (MF) in the US and Europe.
Mycosis Fungoides (MF) Epidemiology
The Mycosis Fungoides (MF) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report is segmented by incident population, sub type specific incident population, stage-specific incidenct population, gender-specific incident population and diagnosed cases of Mycosis Fungoides (MF).
The DelveInsight report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.
According to DelveInsight, the incident population of Mycosis Fungoides (MF) was estimated to be 5,078 [7MM] in 2018. United States accounts for the highest Mycosis Fungoides (MF) cases, followed by EU5 (Germany, France, Italy, Spain & UK) and Japan. Among the EU5 countries UK had the highest incident patient population of Mycosis Fungoides (MF), followed by Germany.
Mycosis Fungoides (MF) Drug Chapters
This segment of the Mycosis Fungoides (MF) report encloses the detailed analysis of marketed drugs and late stage (Phase-III) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
There are currently eight approved therapies including Adcetris, Zolinza and Targretin, which are being used for the treatment of Mycosis Fungoides (MF). However these drugs have shown to be effective in managing the Mycosis Fungoides (MF) patches, plaques, and tumors, or for variants showing a similar clinical course. Also these drugs are associated with certain toxicity and subsequently virus are developing resistance against the existing batch of antivirals highlighting the need of innovative drugs. Curative drugs and vaccines remains one of the major unmet medical need in this space. Detailed chapters for all of these marketed drugs along with other promising candidates like Mechlorethamine and Uvadex have been covered in the report.
Mycosis Fungoides (MF) Market Outlook
The Mycosis Fungoides (MF) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the global market of Mycosis Fungoides (MF) was estimated to be USD 467.11 million in 2018. The United States accounts for the largest market size of Mycosis Fungoides (MF), in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain), and Japan.
The dynamics of Mycosis Fungoides (MF) market is anticipated to change in the coming years owing to the expected launch of emerging therapies during the forecasted period 2019-2028. Launch of potential therapies may increase market size in the coming years, assisted by an increase in diagnosed incident population of Mycosis Fungoides (MF). Upcoming therapies have the potential to create a significant positive shift in the Mycosis Fungoides (MF) market size. The United States accounts for the largest market size of Mycosis Fungoides (MF), in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain), and Japan.
Mycosis Fungoides (MF) Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The market size of Mycosis Fungoides (MF) includes the drug-uptake for individual therapies, which is further segmented on the basis of market size and market share by Line of therapy and Route of Administration.
To counter current unmet needs of the market and to provide better treatment options for Mycosis Fungoides (MF), several companies are working robustly on developing new therapies with novel mechanism of action.
Mycosis Fungoides (MF) Report Insights
• Patient Population
• Therapeutic Approaches
• Pipeline Analysis
• Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies
Mycosis Fungoides (MF) Report Key Strengths
• 10 Year Forecast
• 7MM Coverage
• Epidemiology Segmentation
• Drugs Uptake
• Highly Analyzed Market
• Key Cross Competition
Mycosis Fungoides (MF) Report Assessment
• Current Treatment Practices
• Unmet Needs
• Detailed Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers
Key Benefits
• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the Mycosis Fungoides (MF) market.
• Organize sales and marketing efforts by identifying the best opportunities for Mycosis Fungoides (MF) market.
• To understand the future market competition in the Mycosis Fungoides (MF) market.
